Xu Yu, Shi Chang, Qian Jiejing, Yu Xiao, Wang Shasha, Shao Li, Yu Wenjuan
Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China.
Zhejiang provincial Key laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China.
Clin Transl Oncol. 2025 May;27(5):2347-2353. doi: 10.1007/s12094-024-03710-2. Epub 2024 Sep 25.
Studies have shown that the gut microbiota may affect anti-tumor immunity by regulating the host immune system and tumor microenvironment. To date, little is known about whether the gut microbiota underlies the occurrence of diffuse large B-cell lymphoma (DLBCL) and drug resistance.
In the present study, we compared the gut microbiota structure of fecal samples from 26 patients with primary DLBCL, 28 patients with relapsed and refractory (RR) DLBCL, and 30 healthy people.
Notably, Fusobacteria (from phylum to species) was enriched in the primary group. A decrease of Fusobacterium and an increase of Enterococcus were found in the RR group. PICRUSt analysis found that genes related to cytochrome P450 were upregulated in the RR group compared to the primary group, which likely contributes to the occurrence of DLBCL and the formation of drug resistance.
Our study provides further evidence for the relationship between gut microbiota and DLBCL and the formation of drug resistance, highlighting the potential significance of the bacterial variations may be used as new biomarkers of DLBCL.
研究表明，肠道微生物群可能通过调节宿主免疫系统和肿瘤微环境来影响抗肿瘤免疫。迄今为止，关于肠道微生物群是否是弥漫性大B细胞淋巴瘤（DLBCL）发生及耐药性的基础知之甚少。
在本研究中，我们比较了26例原发性DLBCL患者、28例复发难治性（RR）DLBCL患者和30名健康人的粪便样本的肠道微生物群结构。
值得注意的是，厚壁菌门（从门到种）在原发性组中富集。RR组中发现梭杆菌减少，肠球菌增加。PICRUSt分析发现，与细胞色素P450相关的基因在RR组中相对于原发性组上调，这可能促成了DLBCL的发生和耐药性的形成。
我们的研究为肠道微生物群与DLBCL及耐药性形成之间的关系提供了进一步证据，突出了细菌变异作为DLBCL新生物标志物的潜在意义。
